» Articles » PMID: 16002972

Clinical Features of 5,628 Primary Lung Cancer Patients: Experience at Mayo Clinic from 1997 to 2003

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2005 Jul 9
PMID 16002972
Citations 195
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: To improve the current understanding of the etiology and natural history of primary lung cancer, we need to study the dynamic changes of clinical presentation and prognosis among a large number of patients with newly diagnosed lung cancer. In this report, we present the clinical features and survival rates up to 5 years of a patient cohort.

Design: We identified 5,628 primary lung cancer patients between 1997 and 2002 and followed them through 2003 using multiple, complementary resources.

Measurements And Results: Of the 5,628 patients, 58% were men with a mean age at lung cancer diagnosis of 66 years, and 42% were women with a mean age at diagnosis of 64 years. Ten percent were < 50 years, and 8% were > 80 years at diagnosis. A tobacco smoking history was present in 89% of patients, and 40% were smoking at the time of diagnosis. The estimated overall 5-year survival rates of patients with non-small cell lung cancer (NSCLC) by disease stage was as follows: IA, 66%; IB, 53%; IIA, 42%; IIB, 36%; IIIA, 10%; IIIB, 12%; and IV, 4%. The 5-year survival rate of patients with small cell lung cancer was 22% for limited disease and 1% for extensive disease. Approximately 50% of all patients are participants in one or more research studies, and nearly 75% of these patients have donated biological specimens for research.

Conclusion: The survival rate of this cohort of lung cancer patients was slightly improved compared with earlier reports, particularly for patients with low-stage NSCLC. Our patient and biospecimen resource has enabled us to obtain timely results from clinical and translational research of lung cancer.

Citing Articles

Genome-wide CRISPR-Cas9 screening identifies ITGA8 responsible for abivertinib sensitivity in lung adenocarcinoma.

Li X, Zhu G, Cao P, Huang H, Chen Y, Chen C Acta Pharmacol Sin. 2025; .

PMID: 39809840 DOI: 10.1038/s41401-024-01451-0.


Targeted therapy‑associated cardiotoxicity in patients with stage‑IV lung cancer with or without cardiac comorbidities.

Peng Y, Li D, Wampfler J, Luo Y, Kumar A, Gu Z Oncol Rep. 2024; 53(2.

PMID: 39704259 PMC: 11683451. DOI: 10.3892/or.2024.8858.


Real-world treatment patterns and clinical outcomes in -mutant locally advanced lung adenocarcinoma: A multi-center cohort study.

Bi N, Xu K, Ge H, Chen M, E M, Zhang L J Natl Cancer Cent. 2024; 3(1):65-71.

PMID: 39036309 PMC: 11256516. DOI: 10.1016/j.jncc.2022.11.003.


The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Zhang T, Wang J, Wang D, Xu K, Wu L, Wang X J Natl Cancer Cent. 2024; 2(1):33-40.

PMID: 39035216 PMC: 11256537. DOI: 10.1016/j.jncc.2021.11.003.


Lung adenocarcinoma patients with -rearranged tumors by sex and smoking intensity.

Peng Y, Ernani V, Liu D, Guo Q, Hopps M, Cappelleri J Heliyon. 2024; 10(7):e28285.

PMID: 38560203 PMC: 10981064. DOI: 10.1016/j.heliyon.2024.e28285.